Clinical Trial Detail

NCT ID NCT03278782
Title Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

peripheral T-cell lymphoma

Therapies

Romidepsin

Pembrolizumab + Romidepsin

Age Groups: adult senior

No variant requirements are available.